New stem cell treatment offers hope for ALS patients
Disease control
TEMPORARILY_NOT_AVAILABLE
This trial provides expanded access to RAPA-501, a therapy made from a patient's own immune cells, for people with ALS. The goal is to control the disease and slow its progression. Participants must be 18 or older and have a confirmed ALS diagnosis.
Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC